


phyto
psyche



We are Experiencing a Global Mental Wellness Crisis



~1 Billion

People affected by mental health disorders worldwide¹

\$2.5 Trillion

Annual global economic cost from mental disorders²



The WHO has prioritized mental health as a leading global issue.

- Growing concerns over how effectively we address mental health issues have given rise to an emerging **Neurowellness market**.
- As patients seek new alternatives to traditional “big pharma” solutions for their health and well being needs, initial research into psychedelic compounds has identified **remarkable potential** for new, more effective treatments.
- As psychedelic stigmas are debunked and new innovations are developed, a nascent industry is building itself – with a **clear path to commercialization**.

¹ Global Health Data Exchange <http://ghdx.healthdata.org/gbd-results-tool>


² <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007565/>

The Perception of Psychedelics is Changing

Lack of effective treatments for mental health disorders represents a significant unmet need for patients worldwide.

Traditional SSRI's (Lexapro, Wellbutrin, Prozac, Zoloft, etc.) are mainstays for the treatment of depression. Xanax and Valium continue to see wide use for the management of anxiety and stress.

Although antidepressant sales are on the rise



up to

1 in 3

patients see symptoms return

according to research at Johns Hopkins.

Searching for more effective treatment methods, companies and research institutions have turned to **entheogens** – or psychedelic drugs – for their potential to transform how mental wellness is managed today.



**320
MILLION**

People affected by depression globally



**280
MILLION**

People affected by anxiety globally

More than 20% of U.S. adults experienced mental illness in 2020¹




Mental health and substance abuse disorders account for **1 out of every 8** emergency room visits

Less than half of all U.S. adults with mental illness received treatment in 2020



Prescriptions for antidepressants, anti-anxiety and anti-insomnia medications **increased 21%** at the onset of the COVID-19 pandemic



17 million people, or 32.1% of U.S. adults with mental illness also experience substance use disorders



Suicide in the U.S. has **increased 35%** since 1999




People with depression have a **40% higher risk of developing cardiovascular and metabolic diseases** than the general population



POTENTIAL INDICATIONS FOR PSYCHEDELICS AS A MEDICINE (PaaM):

Addiction and substance abuse

Post Traumatic Stress Disorder



Anxiety and stress

Depression

Terminal illnesses

¹ National Alliance on Mental Illness: <https://www.nami.org/mhstats>

The Investment Opportunity is Now

We believe there exists an **attractive investment opportunity** yet to be recognized by the financial community at large – just as was seen in the early years of legal cannabis.



By connecting with the right people and providing venture capital to early industry operators, **Phyto helped grow the Cannabis industry from \$4 billion in sales in 2015 to nearly \$25 billion in 2021.**

We have applied this same approach to our new psychedelic-focused fund

phyto
psyche

A decorative graphic of a molecular structure composed of interconnected hexagons and circles in various shades of blue, located to the right of the company name.

Mind Health is the New Wealth

Phyto Partners has opened the Phyto IV fund to provide a managed investment vehicle for accredited investors to take advantage of this opportunity.



Phyto IV is designed with a focus on investments in the Neurowellness space – companies operating with and around the use of psychedelic compounds for the improvement of mental well-being.



After 18 months of diligence, we have vetted a small number of select investment targets that we plan to fund by the end of Q1 2022.


A Nascent Industry Primed for Growth

5

States with full or partial decriminalization (incl. Washington, D.C.)

48

Publicly traded psychedelic companies



PHARMATHER

CORE ONE LABS

MYND™

Numinus

ENVERIC BIOSCIENCES

Cybin

RED LIGHT HOLLAND

GH Research

heading

SILO WELLNESS

COMPASSION Navigating Mental Health Pathways

C Clearmind

MindMed

PSYBIO THERAPEUTICS

UNIVERSAL™ IBOGAINE

AION THERAPEUTICS

field trip

HARMADRUG™

Mindset Pharma

DELIC CORP

SiloPharma

SEELOS ST THERAPEUTICS

BRAXIA SCIENTIFIC

optimi health

EHAVE

TRYP THERAPEUTICS

LOBE SCIENCES

BRIGHT MINDS

MINDCURE

PSYK ETF

BetterLife Pharma

LEVITEE LABS

M2Bio SCIENCES

ALGERNON PHARMACEUTICALS

Novamind

Awakn™ Life Sciences Corp.

wesana™

atai LIFE SCIENCES

Incannex

Revive Therapeutics

neon mind BIOSCIENCES INC.

Filament Health

Small Pharma

psyched wellness

MYDECINE INNOVATIONS GROUP

Strong Industry Connections

- We have curated deep relationships with the leading voices and pioneers in the Psychedelic industry
- Years of thorough diligence at the forefront of innovation gives us unique insight into the evolving sector



PSYCHEDELIC WATER™



The Tide Has Shifted at the FDA

100+

FDA clinical trials of psychedelic compounds are currently ongoing



24

Clinical trials in Phases II and III



6


Academic institutions have opened dedicated psychedelic research centers




- The FDA has granted **breakthrough therapy designations** for MDMA and psilocybin, expediting their development and review due to the potential for substantial improvements over currently available therapies.
- Regulatory pathways and lengthy FDA approval processes will require near-term investments in early clinical and preclinical programs to spur innovation.
- Additional preclinical trials are underway, and the first FDA approval for psychedelic therapies can be expected as early as 2023.

Market Outlook

The nascent psychedelics industry presents a unique investment opportunity as the market rapidly scales.




U.S. Psychedelic Drugs Market Growth Projection¹



¹Data Bridge Market Research, U.S. Psychedelic Drugs Market – Industry Trends and Forecast to 2027

Three drivers of growth in the U.S. psychedelics industry



Heal

Development of clinical treatments for mental health disorders and other related illnesses



Research


Investigation of new chemical entities (NCEs) and other psychedelic technologies



Tech

New tools improving patient access, education, data, marketing, and other services supporting the growth of the industry

Our Investment Thesis



Amid growing public awareness, a renaissance in psychedelic research and an increasing trend toward “conscious capitalism” has revealed an attractive new investment opportunity in the **neurowellness market**.

The neurowellness sector has become one of the fastest-growing and largest markets to emerge in decades, and current regulatory hurdles have created an early-stage funding gap for companies uniquely poised for considerable growth.

We believe that addressing this funding gap will be a key catalyst for rapid market expansion.

Phyto's Strengths

MANAGEMENT EXPERTISE

The portfolio managers, Board of Advisors & network of experienced industry consultants bring proven success.

INDUSTRY EXPERIENCE

The fund will leverage its deep operational and financial expertise, with its network of relationships to accelerate the growth of its portfolio companies.

FINANCIAL STRENGTH

Phyto has emerged as one of the Top Venture Capital investors in the industry.

OPERATIONAL EXPERTISE

Phyto's deep relationships gives insight into the industry where information is often sparse and unreliable.

DEAL SOURCING


Phyto has developed a relevance & understanding of the industry giving us the expertise to manage the myriad legal and regulatory challenges.

ACCESS TO CAPITAL

Phyto provides investors the ability to diversify among geographies, sectors, products and service verticals of the industry.



Target Investment Criteria



Research and Investment are Underway

RESEARCH INSTITUTIONS



PHARMACEUTICAL RESEARCH



Phyto Partners add Strategic Value



Ryan G. Smith
Co-Founder



"Larry & Brett have been incredibly helpful in our networking with new clients and positioning us to scale to new states. We're pumped to have Phyto on our team as we tackle the future."



Josh Rubin
Co-Founder, CEO



DAY THREE LABS

"All of us knew we needed experienced investors with their finger on the pulse of the Cannabis industry. Phyto Partners brought exactly that."



Daniel Carcillo
Founder, CEO



"Wesana has benefited tremendously from our relationship with Phyto Partners. I personally value the personal relationship I have with the team and the market insights they provide."



Rosie Mattio
Founder, CEO



"Phyto Partners have been true partners, lending their insights, facilitating partnerships, participating in co-marketing events and introducing us to other strategic groups."

Management Team



Larry Schnurmacher
MANAGING PARTNER

Larry Schnurmacher is a career investment professional having managed capital for high net worth individuals for over 25 years. After retiring from Morgan Stanley in 2015, he founded Phyto Partners to help investors capitalize on the opportunity in the Cannabis industry. He has invested in 25 privately held cannabis companies since, building Phyto Partners into one of the preeminent venture capital private equity funds in the space, recognized as a Top Cannabis Investment fund by Forbes and BusinessInsider.



Evan Schnurmacher
PORTFOLIO ANALYST

Evan has held several positions creating content and executing digital marketing strategies at Information Television and The Birds Nest Foundation. For the past two years Evan has held sales and client delivery roles at Yext. Evan graduated University of Maryland with a Bachelor of Arts. Evan is responsible for deal sourcing, portfolio company monitoring, and investor relations.



Jonathan Rubin
PORTFOLIO ANALYST

Jonathan has worked as an analyst at Comvest Partners, where he was responsible for identifying and qualifying new investment opportunities. He graduated with a degree in Finance from the University of Florida. Jonathan has analyzed greater than 1,000 cannabis opportunities since 2018 and is responsible for due diligence, deal sourcing, portfolio monitoring and investor reporting.



Michael Sobeck
FOUNDER AND
MANAGING PARTNER

Michael founded Ambria Capital in 2018, investing his own capital into early stage frontier industry companies and non-traditional venture opportunities. With more than 15 years' experience, Michael leads the overall strategy and direction of the firm.



Cody Shandraw
MANAGING PARTNER

Cody is a partner at Ambria Capital, managing market assessment projects and due diligence, including building and maintaining client and partner relationships. He has been a serial entrepreneur from an early age, focused on investing in cutting-edge ideas and out-of-the-box venture opportunities.



Aaron Raub
PARTNER AND
PORTFOLIO MANAGER

Aaron joined Ambria Capital in 2019, spearheading fundamentals review of potential funding opportunities, monitoring current positions and implementing the firm's investment strategy. A seasoned public and private market investor, Aaron specializes in small cap and emerging industries.



Fund Administration and Advisors

ROBINSON BROG

LEGAL COUNSEL
Adam Greene



FUND ADMINISTRATOR
Sam Crispino

Rubin & Associates

ACCOUNTING & AUDIT
Gary Rubin, CPA

Fund Details

FUND NAME:	Phyto IV, LP
DATE LAUNCHED:	February 28, 2022
TOTAL VALUE:	\$2.5M - \$25M at first close
MANAGEMENT FEE:	2%
MINIMUM INVESTMENT:	\$250,000
INVESTMENT PERIOD:	3 year minimum; 10 year fund*
CONTACT:	evan@phytopartners.com

*Life of fund may be prolonged as needed

Appendix

Recent News and Research

The Hub

[Johns Hopkins launches center for psychedelic research](#)

Imperial College London

[The future of psychedelic science](#)

Technology Networks

[Psychedelic Study Links Brain Activity and Behavior](#)

Johns Hopkins Medicine Newsroom

[Psychedelic Drug MDMA May Reawaken 'Critical Period' in Brain to Help Treat PTSD](#)

BBC Science Focus

[The mind-blowing science how psychedelic drugs change your brain](#)

UC Berkeley News

[UC Berkeley launches new center for psychedelic science and education](#)

Newsweek

[Psychedelic Drugs: The Brain Enters a 'Higher State of Consciousness' on LSD and Ketamine](#)



Legal Disclaimer

This material contains confidential and/or privileged information. If you are not the intended recipient, please notify the sender immediately and destroy these contents. Any unauthorized copying, disclosure or distribution of this material is strictly prohibited. This material is for information purposes only and is not an offer to sell or a solicitation of any offer to buy shares or interests in a fund. Any such offer or solicitation may be made only by means of delivery of an approved Offering Memorandum (the “Memorandum”) from Phyto Partners IV, L.P. (the “Fund”) containing important information about the terms of investment, risk factors, conflicts of interest, restrictions on transferability, and other material aspects about the Fund and only in those jurisdictions permitted by law. The Memorandum must be received and reviewed prior to any investment decision. Any person subscribing for an investment must be able to bear the risks involved and must meet the suitability requirements relating to such investments. Some or all alternative investment programs may not be suitable for certain investors. This presentation includes certain information relating to past performance. Past performance is no guarantee of future performance. Such results are presented for illustrative purposes only. The actual performance of the Fund may differ substantially from that set forth herein. The presentation is provided to you with the understanding that as a sophisticated investor, you will understand and accept its inherent limitations, will not rely on it in making any investment decision with respect to the Fund, and will use it only for the purpose of discussing your preliminary interest in investing in the Fund. Nothing contained herein shall constitute any representation or warranty as to future performance. While all of the information prepared in this presentation is believed to be accurate, the Fund makes no express warranty as to the completeness or accuracy of the information. Transactions of the type described herein may involve a high degree of risk, and the value of such instruments may be highly volatile. No representation or assurance can be given that the Fund will meet its investment objectives or avoid losses. The Fund is subject to conflicts of interest. This brief statement does not disclose all the risks and other significant aspects of the strategies of the type described herein, and investors should ensure that they fully understand the terms of the Fund, including the relevant risk factors and any legal, tax and accounting considerations applicable to it prior to investing.

